ORIC® Pharmaceuticals Announces Enozertinib (ORIC-114) Late-Breaking Oral Presentations in EGFR Atypical and EGFR exon 20 NSCLC at the ESMO Asia Congress 2025

Rhea-AI Summary

ORIC Pharmaceuticals (Nasdaq: ORIC) announced two late-breaking oral presentations of Phase 1b data for enozertinib (ORIC-114) at the ESMO Asia Congress 2025 in Singapore (December 5–7, 2025).

The mini-oral (LBA15) on Dec 5, 2025 at 11:38–11:43 a.m. SGT covers previously treated EGFR atypical mutant NSCLC with randomized dose optimization and CNS activity. The proffered paper oral (LBA13) on Dec 6, 2025 at 10:02–10:12 a.m. SGT covers EGFR exon 20 mutant NSCLC in previously treated and treatment-naïve patients. ORIC will host a conference call and webcast on Dec 6, 2025 at 8:00 p.m. ET, with a replay available for 90 days.

News Market Reaction

+3.10%

1 alert

+3.10% News Effect

On the day this news was published, ORIC gained 3.10%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Mini-oral number: LBA15 Proffered paper number: LBA13 Mini-oral time: 11:38–11:43 a.m. SGT +5 more

8 metrics

Mini-oral number LBA15 EGFR atypical mutant NSCLC mini-oral at ESMO Asia Congress 2025

Proffered paper number LBA13 EGFR exon 20 mutant NSCLC proffered paper at ESMO Asia Congress 2025

Mini-oral time 11:38–11:43 a.m. SGT Mini-oral session on December 5, 2025

Proffered paper time 10:02–10:12 a.m. SGT Proffered paper session on December 6, 2025

Conference call time 8:00 p.m. ET ORIC conference call and webcast on December 6, 2025

Conference dates December 5–7, 2025 ESMO Asia Congress 2025 in Singapore

Webcast replay period 90 days Replay availability after December 6, 2025 conference call

52-week range $3.8951–$14.93 52-week low and high before this news

Market Reality Check

Price: $10.76 Vol: Volume 760,075 is at 0.59...

low vol

$10.76 Last Close

Volume Volume 760,075 is at 0.59x the 20-day average of 1,289,030 shares. low

Technical Price $9.69 is trading above the 200-day MA at $9.42.

Peers on Argus

Before this announcement, ORIC traded at $9.69 (down 1.38%). Peers were mixed, w...

Before this announcement, ORIC traded at $9.69 (down 1.38%). Peers were mixed, with NUVB, MAZE, RAPP and ATNF up between 0.28% and 2.92%, while ELVN was down 6.1%, suggesting stock-specific rather than broad sector drivers.

Common Catalyst One peer, NUVB, also reported positive clinical trial data in oncology on the same day.

Historical Context

5 past events · Latest: Dec 05 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Dec 05	EGFR exon 20 data	Positive	-4.4%	Phase 1b enozertinib EGFR exon 20 data with strong systemic and CNS activity.
Dec 05	Inducement grants	Neutral	-4.4%	Inducement stock options and RSUs granted to new non-executive employees.
Dec 05	HER2 exon 20 data	Positive	-3.5%	Phase 1b enozertinib data in HER2 exon 20 NSCLC with notable disease control.
Dec 04	EGFR atypical data	Positive	+3.8%	Enozertinib Phase 1b data in EGFR atypical NSCLC showing strong CNS activity.
Dec 03	ESMO presentations	Positive	+3.1%	Announcement of late-breaking enozertinib oral presentations and investor call.

Pattern Detected

Recent enozertinib clinical updates showed mixed price reactions, with two positive moves and two selloffs despite similarly upbeat efficacy and safety data.

Recent Company History

Over early December 2025, ORIC issued a series of enozertinib Phase 1b updates at the ESMO Asia Congress 2025, highlighting CNS activity and encouraging ORR across EGFR atypical, EGFR exon 20 and HER2 exon 20 NSCLC populations. Doses around 80 mg QD were repeatedly selected as potential Phase 3 levels. Alongside, the company reported inducement equity grants. Market reactions alternated between gains and pullbacks, indicating that positive clinical signals did not always translate into sustained upside.

Market Pulse Summary

This announcement highlights two late-breaking oral presentations of Phase 1b enozertinib data in EG...

Analysis

This announcement highlights two late-breaking oral presentations of Phase 1b enozertinib data in EGFR atypical and EGFR exon 20 mutant NSCLC at ESMO Asia Congress 2025, plus an investor call on December 6, 2025. Recent history shows mixed price reactions to similarly positive clinical updates, underscoring event-driven volatility. Investors may focus on detailed efficacy and CNS activity metrics once the full data are reviewed, along with ORIC’s cash position and ongoing prioritization around enozertinib from prior regulatory filings.

Key Terms

her2, nsclc, cns

3 terms

her2 medical

"a Highly Selective, Brain Penetrant EGFR and HER2 Inhibitor, in Previously Treated NSCLC"

HER2 is a protein found on the surface of some cancer cells, especially certain breast cancers. When a cancer has too much HER2, it can grow more quickly and be more aggressive. Knowing about HER2 helps doctors choose the best treatments to target these specific cancer cells.

nsclc medical

"EGFR Atypical and EGFR exon 20 NSCLC at the ESMO Asia Congress 2025"

NSCLC stands for non-small cell lung cancer, which is the most common type of lung cancer. It develops in the lungs and can spread to other parts of the body, making it serious but often treatable if caught early. Understanding NSCLC helps people recognize the importance of lung health and early detection.

cns medical

"Randomized Dose Optimization and CNS Activity"

CNS stands for the central nervous system, the brain and spinal cord that control thought, movement and bodily functions. For investors, CNS-focused products and research matter because therapies aimed at this “delicate wiring” are scientifically challenging, often carry higher development and regulatory risk, and can take longer to prove safe and effective — but successful treatments also tend to command large markets and premium pricing.

AI-generated analysis. Not financial advice.

Company to host a conference call and webcast on Saturday, December 6, 2025, at 8:00 pm ET

SOUTH SAN FRANCISCO and SAN DIEGO, Dec. 03, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced two late-breaking oral presentations highlighting data from a Phase 1b trial of enozertinib (ORIC-114) at the ESMO Asia Congress 2025 taking place December 5-7, 2025 in Singapore. The mini-oral presentation will focus on data in previously treated patients with EGFR atypical mutant NSCLC, and the proffered paper oral presentation will focus on data in previously treated and treatment-naïve patients with EGFR exon 20 mutant NCSLC.

Mini-oral presentation details:
Title:	Enozertinib (ORIC-114), a Highly Selective, Brain Penetrant EGFR and HER2 Inhibitor, in Previously Treated NSCLC with EGFR Atypical Mutations: Randomized Dose Optimization and CNS Activity
Presentation Number:	LBA15
Session Type and Title:	Mini Oral session 1: Thoracic malignancies
Lecture Date and Time:	Friday, December 5, 2025; 11:38 – 11:43 a.m. SGT

Proffered paper oral presentation details:
Title:	Enozertinib (ORIC-114), a Highly Selective, Brain Penetrant EGFR and HER2 Inhibitor, in EGFR Exon 20 Mutant NSCLC: Randomized Dose Optimization and CNS Activity
Presentation Number:	LBA13
Session Type and Title:	Proffered Paper session: Thoracic malignancies
Lecture Date and Time:	Saturday, December 6, 2025; 10:02 – 10:12 a.m. SGT

Full late-breaking abstracts are available for public viewing via the ESMO Asia Congress website.

Conference Call and Webcast Details
In conjunction with the ESMO Asia Congress, ORIC will host a conference call and webcast on Saturday, December 6, 2025, at 8:00 pm ET. To join the conference call via phone and participate in the live Q&A session, please pre-register online here to receive a telephone number and unique passcode required to enter the call. A live webcast and audio archive of the conference call will be available through the investor section of ORIC’s website at www.oricpharma.com. The webcast will be available for replay for 90 days following the presentation.

About ORIC Pharmaceuticals, Inc.
ORIC Pharmaceuticals is a clinical stage biopharmaceutical company dedicated to improving patients’ lives by Overcoming Resistance In Cancer. ORIC’s clinical stage product candidates include (1) ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 (PRC2) via the EED subunit, being developed for prostate cancer, and (2) enozertinib (ORIC-114), a brain-penetrant inhibitor that selectively targets EGFR exon 20, EGFR atypical, and HER2 exon 20 mutations, being developed across multiple genetically defined cancers. ORIC has offices in South San Francisco and San Diego, California. For more information, please go to www.oricpharma.com, and follow us on X or LinkedIn.

Contact:

Dominic Piscitelli, Chief Financial Officer
dominic.piscitelli@oricpharma.com
info@oricpharma.com

FAQ

When will ORIC present enozertinib (ORIC-114) data at ESMO Asia 2025?

Two presentations: mini-oral LBA15 on Dec 5, 2025, 11:38–11:43 a.m. SGT and proffered paper LBA13 on Dec 6, 2025, 10:02–10:12 a.m. SGT.

What patient groups are covered in the ORIC enozertinib ESMO Asia presentations?

The mini-oral focuses on previously treated EGFR atypical mutant NSCLC; the proffered paper covers previously treated and treatment‑naïve EGFR exon 20 mutant NSCLC.

How can investors access ORIC's conference call and webcast on Dec 6, 2025?

ORIC will host a conference call and live webcast on Dec 6, 2025 at 8:00 p.m. ET; pre-registration is required for phone access and the webcast replay will be on ORIC's investor website for 90 days.

What topics do the enozertinib ESMO abstracts emphasize?

Both abstracts highlight randomized dose optimization and CNS activity of enozertinib in EGFR/HER2‑driven NSCLC populations.

Where can I find the full late‑breaking abstracts for ORIC's enozertinib presentations?

Full late‑breaking abstracts are available for public viewing on the ESMO Asia Congress 2025 website.

Which ORIC presentation at ESMO Asia 2025 is labeled LBA13 and what is its focus?

Presentation LBA13 is the proffered paper oral on Dec 6, 2025, focusing on enozertinib in EGFR exon 20 mutant NSCLC including previously treated and treatment‑naïve patients.